What I'll Be Looking for Next in Moderna's Coronavirus Vaccine Trial

Shares of Moderna (NASDAQ:MRNA) climbed 20% in a single trading session (May 18), after the biotech company announced encouraging interim results from an ongoing phase 1 trial of its vaccine for COVID-19, the illness caused by the novel coronavirus.

Now the company is beginning a phase 2 trial to further investigate safety, immune response, and any potential adverse effects.